Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults
about
Duloxetine in adults with ADHD: a randomized, placebo-controlled pilot studyADHD and adolescent athletes.Pharmacological Treatment of ADHD in Addicted Patients: What Does the Literature Tell Us?Off-label use of atomoxetine in adults: is it safe?Toward personalized smoking-cessation treatment: Using a predictive modeling approach to guide decisions regarding stimulant medication treatment of attention-deficit/hyperactivity disorder (ADHD) in smokers.A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function.Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction.Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression.Adult ADHD and suicide.Aiming for remission in adults with attention-deficit/hyperactivity disorder: The primary care goal.Considerations in the Use of Stimulants in Sport.Adult ADHD: A new disease?A randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapy.Long-term safety and tolerability of atomoxetine in Japanese adults with attention deficit hyperactivity disorder.
P2860
Q28266572-131B156F-EB9B-4795-ACFA-23427B3D27E0Q33764804-B8A904EB-68BA-4071-AAD8-C5510F51D9A1Q33919950-DC8D861C-B206-4382-BACC-9AB573786F60Q34618993-7A9C8631-23C7-4825-866F-3770AF71805AQ35588731-CEBA9026-6709-448E-881D-219DCFF37DDBQ37104132-25F4A997-A037-4D87-88B5-B8F79E82C0C9Q38060572-5D715BA8-1CA6-4D1F-8B4A-0410E656B6A9Q38065287-CA150949-5D43-489F-830D-15EBD98EDCCFQ38118231-91E077E6-4122-4E63-B064-BB5A84EA1AFFQ38234075-635F1BCD-3005-4015-8F5A-8F356BF683A6Q38348042-59DF5FD1-C968-48B4-8773-7C7DAA002486Q38681921-4CFB9B6D-D14D-4BB9-BE6B-98037CC435B8Q38799949-116C8359-47E0-4188-B257-11B81B9DB282Q42361284-08E8E810-F7CB-406C-932E-D0AC9BB84603Q45752906-4E1E9519-F33A-4EB7-B66B-EF26D278D260
P2860
Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Efficacy and tolerability of p ...... peractivity disorder in adults
@ast
Efficacy and tolerability of p ...... peractivity disorder in adults
@en
Efficacy and tolerability of p ...... peractivity disorder in adults
@nl
type
label
Efficacy and tolerability of p ...... peractivity disorder in adults
@ast
Efficacy and tolerability of p ...... peractivity disorder in adults
@en
Efficacy and tolerability of p ...... peractivity disorder in adults
@nl
prefLabel
Efficacy and tolerability of p ...... peractivity disorder in adults
@ast
Efficacy and tolerability of p ...... peractivity disorder in adults
@en
Efficacy and tolerability of p ...... peractivity disorder in adults
@nl
P2093
P2860
P921
P1433
P1476
Efficacy and tolerability of p ...... peractivity disorder in adults
@en
P2093
Myooran Canagaratnam
Paramala J Santosh
Sanjida Sattar
P2860
P304
P356
10.2165/11593070-000000000-00000
P407
P577
2011-09-01T00:00:00Z
P5875
P6179
1024124352